![](/img/cover-not-exists.png)
Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios
Suh, K, Carlson, JJ, Garrison, LPVolume:
19
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2016.03.200
Date:
May, 2016
File:
PDF, 80 KB
english, 2016